Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).

Immunosuppressive, corticosteroid use ups herpes zoster risk in Filipinos with SLE

17 Dec 2019

Among Filipino patients with systemic lupus erythematosus (SLE), the use of immunosuppressive and corticosteroid contributes to an increased risk of developing herpes zoster (HZ) infection, a study has found. The risk is even higher in lupus nephritis patients exposed to intravenous cyclophosphamide and mycophenolate mofetil (MMF).

The study included 65 adult SLE patients (mean age, 36.75 years; 93.8 percent female) who developed HZ and 130 matched SLE controls without HZ seen at the University of Santo Tomas Lupus Clinics. Researchers evaluated clinical characteristics, SLE disease activity and immunosuppressive in relation to the risk of HZ.

Mean SLE disease duration at first HZ infection was 6.1 years, and four patients had more than one episode of HZ. The infection was localized in most patients (n=63; 97 percent), and two patients (3 percent) disseminated HZ infections.

Compared with those in the non-HZ group, patients in HZ group were exposed to higher doses of prednisone (mean, 18.62 vs 11.73 mg/d; p<0.001) and more frequently used cyclophosphamide (19/65 vs 7/130 patients; p<0.001). Exposure to the combination of cyclophosphamide plus MMF among lupus nephritis patients was associated with the highest risk of HZ infection.

On the other hand, hydroxychloroquine use reduced the risk of HZ by 87 percent (adjusted odds ratio, 0.13; p=0.003). SLE disease activity showed no direct association with the risk.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
27 Nov 2017
The amino sulphonic acid taurine may safely and effectively reduce portal pressure in cirrhotic patients, a study has shown.
Prof. Vincent Wong, Prof. Ray Kim, Dr. Tan Poh Seng, 10 Sep 2019
Chronic hepatitis B (CHB) remains a major public health concern because of its worldwide distribution and potential adverse sequelae, including cirrhosis and hepatocellular carcinoma (HCC). At a recent symposium held during the GIHep Singapore 2019, Professor Vincent Wong from the Chinese University of Hong Kong and Professor Ray Kim from the Stanford University School of Medicine, Stanford, California, US, discussed antiviral treatments for CHB, with a focus on the novel agent tenofovir alafenamide (Vemlidy®). Dr Tan Poh Seng from the National University Hospital, Singapore, chaired the symposium.
26 Nov 2019
Podcast: Professor R. Scott Wright speaks about the potential role of inclisiran in providing durable reductions in LDL-cholesterol levels in patients with atherosclerotic cardiovascular disease.
Jairia Dela Cruz, 12 Dec 2019
Use of isatuximab (Isa) in combination with pomalidomide and dexamethasone (PomDex) appears to lead to more favourable outcomes in elderly patients with relapsed/refractory multiple myeloma (RRMM) as compared with PomDex alone, according to the results of a subgroup analysis of the ICARIA-MM trial presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).